Highlights on molecular mechanisms of MDSC-Mediated Immune Suppression: Paving the way for new working hypotheses

Immunological Investigations

Volumn 41, Issue 6-7, 2012, Pages 722-737

  Solito, Samantha ^a   Pinton, Laura ^b   Damuzzo, Vera ^a   Mandruzzato, Susanna ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Innate Immunity; Myeloid Cells; Myeloid Derived Suppressor Cells; Tolerance

Indexed keywords

CALGRANULIN A; CALGRANULIN B; CCAAT ENHANCER BINDING PROTEIN BETA; CD11B ANTIGEN; CD16 ANTIGEN; CD3 ANTIGEN; COMPLEMENT COMPONENT C5A; FAS LIGAND; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; INTERLEUKIN 1BETA; INTERLEUKIN 4 RECEPTOR ALPHA; INTERLEUKIN 6; PROSTAGLANDIN E2; VASCULOTROPIN;

ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; CANCER PATIENT; CELL EXPANSION; CELL INTERACTION; CELL LINEAGE; DENDRITIC CELL; DOWN REGULATION; HEMATOPOIETIC CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; INFLAMMATION; LYMPHOCYTE PROLIFERATION; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SUPPRESSOR CELL; SURVIVAL; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD; CELL DIFFERENTIATION; CYTOKINES; GENETIC HETEROGENEITY; HUMANS; IMMUNE TOLERANCE; MICE; MYELOID PROGENITOR CELLS; NEOPLASM PROTEINS; NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TUMOR MARKERS, BIOLOGICAL;

EID: 84866939185     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.3109/08820139.2012.678023     Document Type: Article

References (67)

1. Al-Shami, A. , Mahanna, W. , and Naccache, P. H. (1998). Granulocyte-macrophage colonystimulatingfactor-activated signaling pathways in human neutrophils. Selectiveactivation of Jak2, Stat3, and Stat5b. J. Biol. Chem. 273: 1058-1063.
2. Brandau, S. , Trellakis, S. , Bruderek, K. , Schmaltz, D. , Steller, G. , Elian, M. , Suttmann,H. , Schenck, M. , Welling, J. , Zabel, P. , and Lang, S. (2011). Myeloid-derived suppressorcells in the peripheral blood of cancer patients contain a subset of immatureneutrophils with impaired migratory properties. J. Leukoc. Biol. 89: 311-317.
3. Bronte, V. , Chappell, D. B. , Apolloni, E. , Cabrelle, A. , Wang, M. , Hwu, P. , Restifo, N. P. (1999). Unopposed production of granulocyte-macrophage colony-stimulating factorby tumors inhibits CD8 + T cell responses by dysregulating antigen-presenting cellmaturation. J. Immunol. 162: 5728-5737.
4. Bronte, V. , Cingarlini, S. , Marigo, I. , De Santo, C. , Gallina, G. , Dolcetti, L. , Ugel, S. ,Peranzoni, E. , Mandruzzato, S. , and Zanovello, P. (2006). Leukocyte infiltration incancer creates an unfavorable environment for antitumor immune responses: anovel target for therapeutic intervention. Immunol. Invest. 35: 327-357.
5. Bronte, V. , and Zanovello, P. (2005). Regulation of immune responses by L-argininemetabolism. Nat. Rev. Immunol. 5: 641-654.
6. Bunt, S. K. , Yang, L. , Sinha, P. , Clements, V. K. , Leips, J. , and Ostrand-Rosenberg, S. (2007). Reduced inflammation in the tumor microenvironment delays the accumulationof myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 67: 10019-10026.
7. Cheng, P. , Corzo, C. A. , Luetteke, N. , Yu, B. , Nagaraj, S. , Bui, M. M. , Ortiz, M. , Nacken,W. , Sorg, C. , Vogl, T. , Roth, J. , and Gabrilovich, D. I. (2008). Inhibition of dendriticcell differentiation and accumulation of myeloid-derived suppressor cells in cancer isregulated by S100A9 protein. J. Exp. Med. 205: 2235-2249.
8. Chioda, M. , Peranzoni, E. , Desantis, G. , Papalini, F. , Falisi, E. , Solito, S. , Mandruzzato,S. , and Bronte, V. (2011). Myeloid cell diversification and complexity: an old conceptwith new turns in oncology. Cancer Metastasis Rev. 30: 27-43.
9. Choi, J. , Suh, B. , Ahn, Y. O. , Kim, T. M. , Lee, J. O. , Lee, S. H. , and Heo, D. S. (2012). CD15( +)/CD16 (low) human granulocytes fromterminal cancer patients: granulocyticmyeloidderivedsuppressor cells that have suppressive function. Tumour Biol. 33: 121-129.
10. Curran, C. S. , Evans, M. D. , and Bertics, P. J. (2011). GM-CSF production by glioblastomacells has a functional role in eosinophil survival, activation, and growth factorproduction for enhanced tumor cell proliferation. J. Immunol. 187: 1254-1263.
11. Diaz-Montero, C. M. , Salem, M. L. , Nishimura, M. I. , Garrett-Mayer, E. , Cole, D. J. , andMontero, A. J. (2009). Increased circulating myeloid-derived suppressor cells correlatewith clinical cancer stage, metastatic tumor burden, and doxorubicincyclophosphamidechemotherapy. Cancer Immunol. Immunother. 58: 49-59.
12. Dolcetti, L. , Peranzoni, E. , Ugel, S. , Marigo, I. , Fernandez Gomez, A. , Mesa, C. , Geilich,M. , Winkels, G. , Traggiai, E. , Casati, A. , Grassi, F. , and Bronte, V. (2010). Hierarchyof immunosuppressive strength among myeloid-derived suppressor cell subsets isdetermined by GM-CSF. Eur. J. Immunol. 40: 22-35.
13. Ezernitchi, A. V. , Vaknin, I. , Cohen-Daniel, L. , Levy, O. , Manaster, E. , Halabi, A. ,Pikarsky, E, Shapira, L. , and Baniyash, M. (2006). TCR zeta down-regulationunder chronic inflammation is mediated by myeloid suppressor cells differentiallydistributed between various lymphatic organs. J. Immunol. 177: 4763-4772.
14. Filipazzi, P. , Huber, V. , and Rivoltini, L. (2012). Phenotype, function and clinical implicationsof myeloid-derived suppressor cells in cancer patients. Cancer Immunol. Immunother. 61: 255-263.
15. Filipazzi, P. , Valenti, R. , Huber, V. , Pilla, L. , Canese, P. , Iero, M. , Castelli, C. , Mariani, L. ,Parmiani, G. , and Rivoltini, L. (2007). Identification of a new subset of myeloidsuppressor cells in peripheral blood of melanoma patients with modulation by agranulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J. Clin. Oncol. 25: 2546-2553.
16. Finke, J. , Ko, J. , Rini, B. , Rayman, P. , Ireland, J. , and Cohen, P. (2011). MDSC as amechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int. Immunopharmacol. 11: 856-861.
17. Gabrilovich, D. , Ishida, T. , Oyama, T. , Ran, S. , Kravtsov, V. , Nadaf, S. , and Carbone, D. P. (1998). Vascular endothelial growth factor inhibits the development of dendritic cellsand dramatically affects the differentiation of multiple hematopoietic lineagesin vivo. Blood 92: 4150-4166.
18. Gabrilovich, D. I. , Bronte, V. , Chen, S. H. , Colombo, M. P. , Ochoa, A. , Ostrand-Rosenberg,S. , and Schreiber, H. (2007). The terminology issue for myeloid-derived suppressorcells. Cancer Res 67: 425; author reply 426.
19. Gabrilovich, D. I. , and Nagaraj, S. (2009). Myeloid-derived suppressor cells as regulatorsof the immune system. Nat. Rev. Immunol. 9: 162-174.
20. Gallina, G. , Dolcetti, L. , Serafini, P. , De Santo, C. , Marigo, I. , Colombo, M. P. , Basso, G. ,Brombacher, F. , Borrello, I. , Zanovello, P. , Bicciato, S. , and Bronte, V. (2006). Tumorsinduce a subset of inflammatory monocytes with immunosuppressive activity onCD8 + T cells. J. Clin. Invest. 116: 2777-2790.
21. Hanson, E. M. , Clements, V. K. , Sinha, P. , Ilkovitch, D. , and Ostrand-Rosenberg, S. (2009). Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4 + andCD8 + T cells. J. Immunol. 183: 937-944.
22. Heikkila, K. , Ebrahim, S. , and Lawlor, D. A. (2008). Systematic review of the associationbetween circulating interleukin-6 (IL-6) and cancer. Eur. J. Cancer 44: 937-945.
23. Huang, B. , Pan, P. Y. , Li, Q. , Sato, A. I. , Levy, D. E, Bromberg, J. , Divino, C. M. , and Chen,S. H. (2006). Gr-1 +CD115 + immature myeloid suppressor cells mediate the developmentof tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 66: 1123-1131.
24. Ilkovitch, D. , and Lopez, D. M. (2009). The liver is a site for tumor-induced myeloidderivedsuppressor cell accumulation and immunosuppression. Cancer Res. 69: 5514-5521.
25. Kuang, D. M. , Zhao, Q. , Xu, J. , Yun, J. P. , Wu, C. , and Zheng, L. (2008). Tumor-educatedtolerogenic dendritic cells induce CD3epsilon down-regulation and apoptosis of Tcells through oxygen-dependent pathways. J. Immunol. 181: 3089-3098.
26. Kusmartsev, S. , Su, Z. , Heiser, A. , Dannull, J. , Eruslanov, E. , Kubler, H. , Yancey, D. ,Dahm, P. , and Vieweg, J. (2008). Reversal of myeloid cell-mediated immunosuppressionin patients with metastatic renal cell carcinoma. Clin. Cancer Res. 14: 8270-8278.
27. Lechner, M. G. , Liebertz, D. J. , and Epstein, A. L. (2010). Characterization of cytokineinducedmyeloid-derived suppressor cells from normal human peripheral bloodmononuclear cells. J. Immunol. 185: 2273-2284.
28. Lechner, M. G. , Megiel, C. , Russell, S. M. , Bingham, B. , Arger, N. , Woo, T. , and Epstein,A. L. (2011). Functional characterization of human Cd33 + and Cd11b + myeloidderivedsuppressor cell subsets induced from peripheral blood mononuclear cellsco-cultured with a diverse set of human tumor cell lines. J. Transl. Med. 9: 90.
29. Li, H. , Han, Y. , Guo, Q. , Zhang, M. , and Cao, X. (2009). Cancer-expanded myeloid-derivedsuppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J. Immunol. 182: 240-249.
30. Mandruzzato, S. , Solito, S. , Falisi, E. , Francescato, S. , Chiarion-Sileni, V. , Mocellin, S. ,Zanon, A. , Rossi, C. R. , Nitti, D. , Bronte, V. , and Zanovello, P. (2009). IL4Ralpha + myeloid-derived suppressor cell expansion in cancer patients. J. Immunol. 182: 6562-6568.
31. Marigo, I. , Bosio, E. , Solito, S. , Mesa, C. , Fernandez, A. , Dolcetti, L. , Ugel, S. , Sonda, N. ,Bicciato, S. , Falisi, E. , Calabrese, F. , Basso, G. , Zanovello, P. , Cozzi, E. ,Mandruzzato, S. and Bronte, V. (2010). Tumor-induced tolerance and immune suppressiondepend on the C/EBPbeta transcription factor. Immunity 32: 790-802.
32. Markiewski, M. M. , DeAngelis, R. A. , Benencia, F. , Ricklin-Lichtsteiner, S. K. , Koutoulaki,A. , Gerard, C. , Coukos, G. , and Lambris, J. D. (2008/0. Modulation of the antitumorimmune response by complement. Nat Immunol 9: 1225-1235.
33. McKenna, K. C. , Beatty, K. M. , Bilonick, R. A. , Schoenfield, L. , Lathrop, K. L. , and Singh,A. D. (2009). Activated CD11b +CD15 +granulocytes increase in the blood of patientswith uveal melanoma. Invest. Ophthalmol. Vis. Sci. 50: 4295-4303.
34. Meyer, C. , Sevko, A. , Ramacher, M. , Bazhin, A. V. , Falk, C. S. ; Osen, W. , Borrello, I. , Kato,M. , Schadendorf, D. , Baniyash, M. , and Umansky, V. (2011). Chronic inflammationpromotes myeloid-derived suppressor cell activation blocking antitumor immunityin transgenic mouse melanoma model. Proc Natl Acad Sci USA 108: 17111-17116.
35. Mihara, M. , Hashizume, M. , Yoshida, H. , Suzuki, M. , and Shiina, M. (2012). IL-6/IL-6receptor system and its role in physiological and pathological conditions. Clin. Sci. (Lond. ) 122: 143-159.
36. Molon, B. , Ugel, S. , Del Pozzo, F. , Soldani, C. , Zilio, S. , Avella, D. , De Palma, A. , Mauri, P. ,Monegal, A. , Rescigno,M. , Savino, B. , Colombo, P. , Jonjic,N. , Pecanic, S. , Lazzarato, L. ,Fruttero, R. , Gasco, A. , Bronte, V. , and Viola, A. (2011). Chemokine nitrationprevents intratumoral infiltration of antigen-specific T cells. J. Exp. Med. 208: 1949-1962.
37. Montero, A. J. , Diaz-Montero, C. M. , Kyriakopoulos, C. E. , Bronte, V. , and Mandruzzato, S. (2012). Myeloid-derived suppressor cells in cancer patients: A clinical perspective. J. Immunother. 35: 107-115.
38. Monti, F. , Szymczuk, S. , Motta, M. R. , Benini, C. , Fattori, P. P. , Pini, E. , Pasquini, E. , Zoli,W. , Amadori, D. , and Ravaioli, A. (1993). GM-CSF production in human adenocarcinomacell lines. J. Biol. Regul. Homeost. Agents 7: 85-91.
39. Morales, J. K. , Kmieciak, M. , Knutson, K. L. , Bear, H. D. , and Manjili. M. H. (2010). GM-CSF is one of the main breast tumor-derived soluble factors involved in thedifferentiation of CD11b-Gr1-bone marrow progenitor cells into myeloid-derivedsuppressor cells. Breast Cancer Res. Treat. 123: 39-49.
40. Nagaraj, S. , Gupta, K. ,Pisarev, V. , Kinarsky, L. , Sherman, S. , Kang, L. , Herber, D. L. ,Schneck, J. , Gabrilovich, D. I. (2007). Altered recognition of antigen is a mechanism ofCD8 + T cell tolerance in cancer. Nat. Med. 13: 828-835.
41. Nagaraj, S. , Nelson, A. , Youn, J. I. , Cheng, P. , Quiceno, D. , and Gabrilovich, D. I. (2012). Antigen-specific CD4 + T cells regulate function of myeloid-derived suppressor cellsin cancer via retrograde MHC class II signaling. Cancer Ress
42. Obermajer, N. , Muthuswamy, R. , Odunsi, K. , Edwards, R. P. , and Kalinski, P. (2011). PGE2-Induced CXCL12 Production and CXCR4 expression controls the accumulationof human MDSCs in ovarian cancer environment. Cancer Res. 71: 7463-7470.
43. Otsuji, M. , Kimura, Y. , Aoe, T. , Okamoto, Y. , and Saito, T. (1996). Oxidative stress bytumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cellreceptor complex and antigen-specific T-cell responses. Proc. Natl. Acad. Sci. USA93: 13119-13124.
44. Parmiani, G. , Castelli, C. , Pilla, L. , Santinami, M. , Colombo, M. P. , and Rivoltini, L. (2007). Opposite immune functions of GM-CSF administered as vaccine adjuvantin cancer patients. Ann. Oncol. 18: 226-232.
45. Peranzoni, E. , Zilio, S. , Marigo, I. , Dolcetti, L. , Zanovello, P. , Mandruzzato, S. , andBronte, V. (2010). Myeloid-derived suppressor cell heterogeneity and subset definition. Curr. Opin. Immunol. 22: 238-244.
46. Poschke, I. , D. Mougiakakos, J. Hansson, G. V. Masucci, and R. Kiessling. 2010. Immature immunosuppressive CD14 +HLA-DR-/low cells in melanoma patientsare Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res 70: 4335-4345.
47. Rodriguez, P. C. , Ernstoff, M. S. , Hernandez, C. , Atkins, M. , Zabaleta, J. , Sierra, R. , andOchoa, A. C. 2009. Arginase I-producing myeloid-derived suppressor cells in renal cellcarcinoma are a subpopulation of activated granulocytes. Cancer Res. 69: 1553-1560.
48. Rodriguez, P. C. , and Ochoa, A. C. (2008). Arginine regulation by myeloid derived suppressorcells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol. Rev. 222: 180-191.
49. Rokhlin, O. W. , Griebling, T. L. , Karassina, N. V. , Raines, M. A. , and Cohen, M. B. (1996). Human prostate carcinoma cell lines secrete GM-CSF and express GM-CSF-receptoron their cell surface. Anticancer Res. 16: 557-563.
50. Schule, J. , Bergkvist, L. , Hakansson, L. , Gustafsson, B. , and Hakansson, A. (2002). Down-regulation of the CD3-zeta chain in sentinel node biopsies from breast cancerpatients. Breast Cancer Res. Treat. 74: 33-40.
51. Serafini, P. , Meckel, K. , Kelso, M. , Noonan, K. , Califano, J. , Koch, W. , Dolcetti, L. , Bronte,V. , and Borrello, I. (2006). Phosphodiesterase-5 inhibition augments endogenousantitumor immunity by reducing myeloid-derived suppressor cell function. J. Exp. Med. 203: 2691-2702.
52. Serafini, P. , Mgebroff, S. , Noonan, K. , and Borrello, I. (2008). Myeloid-derived suppressorcells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 68: 5439-5449.
53. Sinha, P. , Chornoguz, O. , Clements, V. K. , Artemenko, K. A. , Zubarev, R. A. , and Ostrand-Rosenberg, S. (2011). Myeloid-derived suppressor cells express the death receptorFas and apoptose in response to T cell-expressed FasL. Blood 117: 5381-5390.
54. Sinha, P. , Clements, V. K. , Fulton, A. M. , and Ostrand-Rosenberg, S. (2007). Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressorcells. Cancer Res. 67: 4507-4513.
55. Solito, S. , Bronte, V. , and Mandruzzato, S. (2011a). Antigen specificity of immune suppressionby myeloid-derived suppressor cells. J. Leukoc. Biol. 90: 31-36.
56. Solito, S. , Falisi, E. , Diaz-Montero, C. M. , Doni, A. , Pinton, L. , Rosato, A. , Francescato, S. ,Basso, G. , Zanovello, P. , Onicescu, G. , Garrett-Mayer, E. , Montero, A. J. , Bronte, V. ,and Mandruzzato, S. (2011b). A human promyelocytic-like population is responsiblefor the immune suppression mediated by myeloid-derived suppressor cells. Blood118: 2254-2265.
57. Sonda, N. , Chioda, M. , Zilio, S. , Simonato, F. , and Bronte, V. (2011). Transcription factorsin myeloid-derived suppressor cell recruitment and function. Curr. Opin. Immunol. 23: 279-285.
58. Song, X. , Krelin, Y. , Dvorkin, T. , Bjorkdahl, O. , Segal, S. , Dinarello, C. A. , Voronov, E. , andApte, R. N. (2005). CD11b +Gr-1 + immature myeloid cells mediate suppression of Tcells in mice bearing tumors of IL-1beta-secreting cells. J. Immunol. 175: 8200-8208.
59. Srivastava, M. K. , Bosch, J. J. , Thompson, J. A. , Ksander, B. R. , Edelman, M. J. , andOstrand-Rosenberg, S. (2008). Lung cancer patients' CD4( +) T cells are activatedin vitro by MHC II cell-based vaccines despite the presence of myeloid-derivedsuppressor cells. Cancer Immunol. Immunother. 57: 1493-1504.
60. Srivastava, M. K. , Sinha, P. Clements, V. K. , Rodriguez, P. , and Ostrand-Rosenberg, S. (2010). Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystineand cysteine. Cancer Res 70: 68-77.
61. Stepkowski, S. M. , Chen, W. , Ross, J. A. , Nagy, Z. S. , and Kirken, R. A. (2008). STAT3: animportant regulator of multiple cytokine functions. Transplantation 85: 1372-1377.
62. Ugel, S. , Delpozzo, F. , Desantis, G. , Papalini, F. , Simonato, F. , Sonda, N. , Zilio, S. , andBronte, V. (2009). Therapeutic targeting of myeloid-derived suppressor cells. CurrOpin Pharmacol 9: 470-481.
63. Vincent, J. , Mignot, G. , Chalmin, F. , Ladoire, S. , Bruchard, M. , Chevriaux, A. , Martin, F. ,Apetoh, L. , Rebe, C. , and Ghiringhelli, F. (2010). 5-Fluorouracil selectively killstumor-associated myeloid-derived suppressor cells resulting in enhanced T celldependentantitumor immunity. Cancer Res. 70: 3052-3061.
64. Waight, J. D. , Hu, Q. , Miller, A. , Liu, S. , and Abrams, S. I. (2011). Tumor-derived G-CSFfacilitates neoplastic growth through a granulocytic myeloid-derived suppressor celldependentmechanism. PLoS One 6: e27690.
65. Youn, J. I. , and Gabrilovich, D. L. (2010). The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur. J. Immunol. 40: 2969-2975.
66. Yuan, X. K. , X. K. Zhao, Y. C. Xia, X. Zhu, and P. Xiao. 2011. Increased circulating immunosuppressiveCD14( +)HLA-DR(-/low) cells correlate with clinical cancer stage andpathological grade in patients with bladder carcinoma. J. Int. Med. Res. 39: 1381-1391.
67. Zea, A. H. , Rodriguez, P. C. , Atkins, M. B. , Hernandez, C. , Signoretti, S. , Zabaleta, J. ,McDermott, D. , Quiceno, D. , Youmans, A. , O'Neill, A. , Mier, J. , and Ochoa, A. C. (2005). Arginase-producing myeloid suppressor cells in renal cell carcinomapatients: a mechanism of tumor evasion. Cancer Res 65: 3044-3048.